Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolvaptan for nephrogenic diabetes insipidus due to AVPR2 mutation
jRCTs031180369Suspended
- Sponsor
- Keyakikai Medical Corporation
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of tolvaptan in Arginine Vasopressin Resistance (AVP-R), sponsored by Keyakikai Medical Corporation. Primary endpoint: Urine volume. Started Apr 2018; status: suspended.
02
Drugs
tolvaptan
03
Conditions
Arginine Vasopressin Resistance (AVP-R)
Beyond the preview
Go deeper on jRCTs031180369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180369.